- TLDR Biotech
- Archive
- Page 6
The Latest Biotech & Pharma Updates
Biotech & Pharma Updates | December 2 - 3, 2024
Maze Therapeutics $115M Series D fuels kidney disease ambitions, Gilead buys ADC discovery option from Tubulis, Janux T-cell engager Ph1b dose escalation data launches stock 50%, GSK's hep B vaccine hopeful sputters in Ph1/2, insult to injury as Applied Therapeutics handed FDA warning letter + 29 more stories
Biotech & Pharma Updates | December 1 - 2, 2024
Novartis signs up to $3B deal for PTC Huntington's asset, Senti Bio's stock launches 400%+ on early Ph1 CAR-NK data, Sanofi earmarks €1B for Beijing-based insulin manufacturing plant, KisoJi lands $41M in equity fuel for TROP2-targeting solid tumor clinical asset + 25 more stories
Biotech & Pharma Updates | November 25 - 26, 2024
Roche paying a pretty penny for Poseida's allogeneic cell therapy ambitions, Amgen's MariTide weight loss Ph2 data isn't enough for investors, Cradle Bio $73M Series B for AI-driven protein design, Roche’s anti-TIGIT mAb misses in lung cancer Ph3 + 26 more stories
Biotech & Pharma Updates | November 24 - 25, 2024
Cassava's much-controversial Alzheimer's hopeful flunks in Ph3, Alnylam whips out the priority review voucher for cardiomyopathy asset, Adcendo's ADC hopes get $135M injection, AstraZeneca touts Truqap prostrate cancer subtype Ph3 win + 27 more stories
Biotech & Pharma Updates | November 21 - 24, 2024
BridgeBio's Attruby lands FDA approval, Roche's Vabysmo touts potentially lucrative (in Asia) Ph3b/4 data in polypoidal choroidal vasculopathy, Nabla Bio's coming for the AI-designed protein crown, ALS hopeful Seelos Therapeutics files for bankruptcy + 21 more stories
Biotech & Pharma Updates | November 20 - 21, 2024
Novartis buys gene therapy's Kate Therapeutics for up to $1.1B, Enveda snags $130M Series C on AI-analyzed plant-derived molecules, Pharma ads might go bye-bye if RFK Jr. has his way, CBER's Peter Marks sees vaccine debates as not "a bad thing", Pyxis Oncology’s PYX-201 Ph1 data doesn't inspire investor confidence + 25 more stories
Biotech & Pharma Updates | November 19 - 20, 2024
Pfizer signs drug discovery partnerships with two Flagship portfolio companies, Samsung Biologics scores a bunch of European manufacturing deal, Novartis and Vyriad partner on in-vivo CAR-T generation, Sage Therapeutics' potentially fatal Ph2 blow, RFK Jr. wants to "blow...up" the FDA + 29 more stories
Biotech & Pharma Updates | November 18 - 19, 2024
Dr. Oz to lead Medicare & Medicaid, “fail fast” biotech venture foundry Jupiter Bioventures launches with $70M, BeiGene (soon to BeOne Medicines) settles Brukinsa generic spat with MSN Pharmaceuticals, AstraZeneca’s Andexxa FDA adcom chances not looking good after “major safety findings” + 31 more stories
Biotech & Pharma Updates | November 17 - 18, 2024
Intellia's rare heart disorder CRISPR therapy looks solid in Ph1, AstraZeneca exercises option for Quell Therapeutics cell therapy, Novartis & Ratio Therapeutics' $745M radiotherapy development partnership, Neurogene stock drops even further as one Rett syndrome gene therapy recipient now in “critical condition” + 29 more stories
